Clinical Trials Arena on MSN
Corcept’s stock up as relacorilant meets OS goal in Phase III ovarian cancer trial
Corcept recently suffered a blow after relacorilant was rejected by the FDA for use in Cushing’s syndrome.
Oncoinvent, a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers, today announces that the first patient has been enrolled at one of the newly activated ...
InvestorsHub on MSN
BioVaxys posts encouraging ovarian cancer data from MVP-S combo trial
BioVaxys Technology Corp. (CSE:BIOV) (USOTC:BVAXF) said it has reported positive early results from its Phase 1B/2 PESCO ...
Avmapki Fakzynja is a type of targeted medicine called a tyrosine kinase inhibitor (TKI). TKIs are used to treat many different types of cancers, including ovarian cancer. Avmapki Fakzynja is ...
When Caitlin Delaney was diagnosed with a rare and aggressive form of ovarian cancer as a mother with two young children, she ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results